Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 8, 2015, Pages 9175-9181

  Zhu, Qiaoliang ^a   Liang, Xiang ^a   Dai, Jing ^b   Guan, Xin ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Third Hospital of Shijiazhuang   (China)

Author keywords

Cell apoptosis; Cell invasion; Lung cancer; PI3K AKT mTOR; SLCO2A1

Indexed keywords

ORGANIC ANION TRANSPORTER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SLCO2A1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; CELL PROLIFERATION; DOWN REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; ORGANIC ANION TRANSPORTERS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 85013026959     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bertolaccini L, Terzi A, Ricchetti F and Alongi F. Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? Ann Transl Med 2015; 3: 25.
2. Zhang S, Liu J, Li H and Cheng Y. Anti-angiogenesis therapy for lung cancer: the shore and the other shore. Oncol Translat Med 2015; 1: 15-19.
3. Kumarakulasinghe NB, van Zanwijk N and Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology 2015; 20: 370-378.
4. Okano M, Sugata Y, Fujiwara T, Matsumoto R, Nishibori M, Shimizu K, Maeda M, Kimura Y, Kariya S, Hattori H, Yokoyama M, Kino K and Nishizaki K. E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology 2006; 118: 343-352.
5. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T and Kuriyama S. Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 2005; 11: 562-566.
6. Wanggren K, Lalitkumar PG, Stavreus-Evers A, Stabi B and Gemzell-Danielsson K. Prostaglandin E2 and F2alpha receptors in the human Fallopian tube before and after mifepristone treatment. Mol Hum Reprod 2006; 12: 577-585.
7. Akaneya Y. The remarkable mechanism of prostaglandin E2 on synaptic plasticity. Gene Regul Syst Bio 2008; 1: 83-9.
8. Van Poucke M, Bourry D, Piumi F, Matthe-Euws M, Van Zeveren A, Chardon P and Peelman LJ. Comparative analysis of a BAC contig of porcine chromosome 13q31-q32 and human chromosome 3q21-q22. BMC Genomics 2005; 6: 133.
9. Banu SK, Arosh JA, Chapdelaine P and Fortier MA. Expression of prostaglandin transporter in the bovine uterus and fetal membranes during pregnancy. Biol Reprod 2005; 73: 230-236.
10. Banu SK, Lee J, Satterfield MC, Spencer TE, Bazer FW and Arosh JA. Molecular cloning and characterization of prostaglandin (PG) transporter in ovine endometrium: role for multiple cell signaling pathways in transport of PGF2alpha. Endocrinology 2008; 149: 219-231.
11. Gao F, Lei W, Diao HL, Hu SJ, Luan LM and Yang ZM. Differential expression and regu-lation of prostaglandin transporter and metabolic enzymes in mouse uterus during blas-tocyst implantation. Fertil Steril 2007; 88: 1256-65.
12. Alzamil HA, Pawade J, Fortier MA and Bernal AL. Expression of the prostaglandin F synthase AKR1B1 and the prostaglandin transporter SLCO2A1 in human fetal membranes in relation to spontaneous term and preterm labor. Front Physiol 2014; 5: 272.
13. Lu R, Kanai N, Bao Y and Schuster VL. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest 1996; 98: 1142-1149.
14. Pucci ML, Bao Y, Chan B, Itoh S, Lu R, Copeland NG, Gilbert DJ, Jenkins NA and Schuster VL. Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities. Am Physiol Soc 1999; 277: R734-R741.
15. Bao Y, Pucci ML, Chan BS, Lu R, Ito S and Schuster VL. Prostaglandin transporter PGT is expressed in cell types that synthesize and release prostanoids. Am J Physiol Renal Physiol 2002; 282: F1103-1110.
16. Pfeifer A, Wojtas B, Oczko-Wojciechowska M, Kukulska A, Czarniecka A, Eszlinger M, Musholt T, Stokowy T, Swierniak M, Stobiecka E, Rusinek D, Tyszkiewicz T, Kowal M, Jarzab M, Hauptmann S, Lange D, Paschke R and Jarzab B. Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues. BMC Med Genomics 2013; 6: 38.
17. Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S and Strongin AY. Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res 2008; 68: 4086-4096.
18. You Y, Yang W, Wang Z, Zhu H, Li H, Lin C and Ran Y. Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell Oncol (Dordr) 2013; 36: 323-331.
19. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W and Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851-1863.
20. Serra V, Markman B, Scaltriti M, Eichhorn PJA, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J and Baselga J. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Res 2008; 68: 8022-8030.
21. Zhang J, Ren H, Yuan P, Lang W, Zhang L and Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 2006; 66: 18-23.
22. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, Sasaguri Y, Nishizawa S and Kohno K. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011; 102: 1007-1013.
23. Hung WC, Tseng WL, Shiea J and Chang HC. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett 2010; 288: 156-161.
24. Sheng L, Tong-Hua M, Lian L and Ming-Chuan Z. Construction of Skp2 shRNA and its effect on lung cancer cell growth. Acta AcademiaE Medicinae Militaris Tertiae 2008; 30: 1275-1278.
25. Chalhoub N and Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
26. Foltran L, Maglio GD, Pella N, Ermacora P, Aprile G, Masiero E and Giovannoni M. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol 2015; 11: 629-640.
27. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, Takamochi K, Suzuki K, Yamada T, Niwa H, Ohashi R, Ogawa H, Mori H, Kitamura H, Kaneko T, Tsuneyoshi T and Sugimura H. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007; 57: 664-671.
28. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba, II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M and Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
29. Network CGAR. Comprehensive genomic ch-aracterization defines human glioblastoma ge-nes and core pathways. Nature 2008; 455: 1061-1068.
30. Zhang X, Lou Y, Wang H, Zheng X, Dong Q, Sun J and Han B. Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells. Med Oncol 2015; 32: 95.
31. Nguyen TT, Tran E, Nguyen TH, Do PT, Huynh TH and Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004; 25: 647-659.